Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS)

Next Previous
Trial Profile

A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tergenpumatucel-L (Primary) ; Docetaxel; Indoximod
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Lumos Pharma; NewLink Genetics Corporation

Most Recent Events

  • 04 Apr 2022 Status changed from active, no longer recruiting to discontinued.
  • 17 May 2019 Status changed from recruiting to active, no longer recruiting.
  • 02 Feb 2016 According to CT.gov record, phase of the trial changed from phase II to phase I/II, official title changed.Also,safety is now included as primary endpoint,treatment arms changed from 1 to 2,planned patient number changed from 59 to 115 and treatment section revised with changes in frequency of drugs administration(i.e.for Tergenpumatucel-L- frequency changed from q2w total 24 doses to q3w total 18 doses for Indoximod it changed from BID to TID).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top